Medtronic (MDT) Receives FDA Approves for Certain Attain Performa, Viva Quad Products
- Top 10 News for 7/18 - 7/22: Netflix Sub Gains Evasive; Microsoft Shares Rip on Results; Tesla Debuts Second Master Plan
- Exclusive: Tesla, SolarCity close to merger agreement
- Wall St. rises, racks up fourth straight week of gains
- Shots Fired, More than a Dozen May Be Dead at Munich Shopping Center
- Baker Hughes Total U.S. Rig Count +15 to 462 (447 Prior)
Medtronic (NYSE: MDT) announced it has received United States Food and Drug Administration (FDA) approval for the Attain Performa Model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-D). The quadripolar lead and devices will be broadly available to physicians in mid-September.
With 16 pacing configurations and shorter spacing between the two center electrodes, the Attain Performa Model 4298 left-heart lead provides additional options for physicians to treat different patient anatomies. The new quadripolar lead reduces the incidence of phrenic nerve stimulation (PNS)1, a potential side effect that results in muscle twitching, hiccups or shortness of breath. The Viva Quad XT device is equipped with the proprietary AdaptivCRT feature, which preserves normal heart rhythms and automatically adjusts to patients' needs to customize therapy. The system includes VectorExpress(TM) technology, which reduces lead programming time to two minutes2 by providing physicians with clinically actionable information to help them select optimal pacing configurations for each patient.
Quadripolar leads (leads with four electrodes) help physicians optimize cardiac resynchronization therapy delivery. The Attain Performa lead addresses the clinical challenges that can compromise lead position, offering implanting physicians more options to maintain lead position and optimize CRT therapy3. The Model 4298 lead has a canted shape, and steroid on all four electrodes for lower pacing thresholds4,5.
"Compared to conventional leads, the additional pacing configurations offered by this system provide implanting physicians more options to optimize CRT delivery, which results in better patient care. Likewise, the narrow-spaced bipole helps avoid phrenic nerve capture," said George H. Crossley, M.D., F.A.C.C., F.H.R.S., associate professor, Vanderbilt Heart and Vascular Institute, in Nashville, Tenn.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exelixis (EXEL) and Ipsen Announces Positive CHMP Opinion for Cabometyx to Treat Advanced RCC
- Valeant Pharma (VRX) Receives FDA CRL on Eye Drops Related to Manufacturing Deficiencies; No NDA Efficacy, Safety Concerns Noted
- Puma Biotech (PBYI) Reports 5-Year Data from PB272's ExteNET Trial
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!